SANKARANA Digitally signed by SANKARANARAYA RAYANAN NAN MUTHU MUTHU KRISHNAN Date: 2025.02.10 KRISHNAN 20:05:17 +05'30'

==> picture [111 x 138] intentionally omitted <==

Apollo Hospitals Enterprise Limited Earnings Update Q3 FY25

==> picture [139 x 648] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Disclaimer

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiaries or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision.

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forwardlooking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.

This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same.

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Content

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

Financial Performance Snapshot & Business Segment wise Update Digital Health & Pharmacy Distribution (Apollo HealthCo) 4-9

Consolidated Financials 11-12 Healthcare Services 14-23 Diagnostics & Retail Health (AHLL) 25-28 Digital Health & Pharmacy Distribution (Apollo HealthCo) 30-37

Annexure 39-40

==> picture [1152 x 6] intentionally omitted <==

==> picture [1152 x 596] intentionally omitted <==

----- Start of picture text -----

Financial Performance Sna shot FY2
p Q3 5
(in ₹ Mio) Revenue GrowthYoY(%) EBITDA(Post Ind AS) Margin GrowthYoY(%) PAT GrowthYoY(%)
Healthcare Services 27,850 13% 6,706 24.1% 14% 3,483 12.5% 21%
7.7%
Offline PD [^] 20,786 14% 1,593 19%
Online PD [^] &
2,737 22% (1,027) Vs (1,322) in Q3F24
24|7
2.4%
566
Total HealthCo 23,524 15% 321 1.4%
AHLL 3,895 15% 342 8.8% 32% (80)
Consolidated 55,269 14% 7,615 13.8% 24% 3,723 6.7% 52%
Apollo HealthCo
----- End of picture text -----

^PD:- Pharmacy Distribution

==> picture [1152 x 6] intentionally omitted <==

==> picture [1152 x 596] intentionally omitted <==

----- Start of picture text -----

Financial Performance Sna shot YTD Dec2
p 4
Growth Growth Growth
(in ₹ Mio) Revenue YoY(%) EBITDA(Post Ind AS) Margin YoY(%) PAT YoY(%)
Healthcare Services 83,255 14% 20,144 24.2% 14% 10,409 12.5% 20%
16%
Offline PD [^] 59,299 15% 4,509 7.6%
Online PD [^] &
7,868 19% (3,196) Vs (4,828) in YTD Dec23
24|7
2.0%
1,312
Total HealthCo 67,167 16% 382 0.6%
1,065 9.2% 32%
AHLL 11,596 15% (228)
Consolidated 162,018 15% 22,521 13.9% 29% 10,563 6.5% 64%
Apollo HealthCo
----- End of picture text -----

^PD:- Pharmacy Distribution

==> picture [1152 x 6] intentionally omitted <==

Lar est Pan India Hos ital Chain g p

==> picture [49 x 56] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

==> picture [1103 x 548] intentionally omitted <==

----- Start of picture text -----

Capacity Operational
Hospitals
Census Beds [1] Census Beds
Overall Total 73 10,169 9,429
Delhi: 5
Amritsar: 1
Noida: 1
45 8,736 7,996
Owned Hospitals
Bilaspur: 1
Kanpur: 1
Lucknow: 1
Indirapuram: 1 Managed Hospitals 6 790 790
Jaipur: 1
Day Surgery & 22 643 643
Cradle (AHLL)
Ahmedabad: 3
1Capacity beds include only census capacity beds and doesn’t include emergency, daycare beds, recovery room, dialysis, endoscopy etc.
Bhopal: 1 Assam: 2
Indore: 1 Kolkata: 2
Nashik: 1
Pune: 1 Bhubaneshwar: 1 Healthcare Services Q3
Mumbai: 3Karimnagar: 1 Bacheli: 1 Vishakhapatnam: 2Rourkela: 1 FY25 Snapshot
Hyderabad: 7
Kakinada: 1
Lavasa:1
150,986 In-patients 5% Revenue 27,850 Mio 13% Nellore: 1 Aragonda: 1 ₹ 162,957 Avg Revenue per Bangalore: 8 Chennai: 12 IP Patient 7% EBITDA 6,706 Mio 14%
Ranipet: 1
Mysore: 1 Trichy: 1
Karur: 1 ₹ 60,839 / day ARPOB [2 ] 8% 24.1%
Overseas (Managed) Margin
Bahrain : 1 Cochin: 1
Madurai: 2
Bangladesh: 1
Karaikudi: 1 68% Occupancy
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

2ARPOB is net of fees paid to “fee for service doctors” which is netted off in the Reported Revenues.

==> picture [81 x 61] intentionally omitted <==

AHLL: Transformin Retail Health throu h access and convenience g g

Apollo Health & Lifestyle Ltd

==> picture [362 x 365] intentionally omitted <==

==> picture [257 x 30] intentionally omitted <==

----- Start of picture text -----

Out-of-Hospital care
----- End of picture text -----

Outpatient Clinics
Diagnostics
Day Surgery centers
Single Specialty Facilities :- Dialysis, Sugar and Dental

==> picture [465 x 28] intentionally omitted <==

----- Start of picture text -----

Organizing the unorganized
----- End of picture text -----

Pathology – Organized chains represent only ~30%
Mother and Child, Specialized Surgical Centers
IVF Centers

==> picture [455 x 223] intentionally omitted <==

----- Start of picture text -----

AHLL Q3 FY25 Snapshot
Revenue 3,895 Mio 15% 2,324 261 Clinics Diagnostics Centers EBITDA 342 Mio 32%
8.8%
Margin
134 200
Dialysis Centers Dental Centers
----- End of picture text -----

Significant opportunity to grow the primary care and diagnostics businesses Plays a vital role in last-mile care delivery, and in ensuring continuum of care for the consumer

==> picture [49 x 56] intentionally omitted <==

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

AHL| India’s Largest Omni-channel Healthcare Platform

Apollo HealthCo Ltd

Apollo 24|7

==> picture [49 x 56] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

Apollo Telehealth*

Offline Pharmacy Distribution

India’s largest Organized Pharmacy Platform with presence in ~1,200 cities/ towns spread across 22 States and 5 union territories.
6,360 Operating Stores as on 31[st] December 2024.
Serving ~ 874,000 customers 24 x 7 everyday.
Private and Generic Label sales at 17.7% (offline).

==> picture [380 x 132] intentionally omitted <==

----- Start of picture text -----

Virtual Doctor Consultation
Online Booking : Hospitals
& Diagnostics
Online Medicine delivery Health Insurance
Patient e-health records
Condition management
----- End of picture text -----

Provides comprehensive remote healthcare services .

Unmatched Size

38 Mn.+ Registered Users – 785,500 Daily Active Users
Offers specialized telehealth solutions like 24/7 Tele-Emergency and TeleConsultancy .
Serving consumers through network of 6,360 pharmacies
Industry-leading Growth at scale
Expands access to healthcare in distant regions , improving quality of life.
Platform GMV: INR 2,687 Cr. in FY24, growth of 73% over FY23.
Operates and maintains Mobile Medical Units/ Mobile Health Units, Patient Facilitation Centres, Digital Dispensaries, and is also engaged in organizing Screening Camps and development of Diagnostic Centres for setting up healthcare awareness programs
YTD Dec24: grew by 11% over YTD Dec23 post re-set of operating model

Full stack digital healthcare platform

First-in-class AI enabled technologies including India’s first Clinical Intelligence Engine

==> picture [72 x 8] intentionally omitted <==

----- Start of picture text -----

Division of AHEL
----- End of picture text -----*

==> picture [455 x 236] intentionally omitted <==

----- Start of picture text -----

Health Co Q3 FY25
Snapshot
Revenue 23,524 Mio 15% 6,360 ~16.4% Outlets Omni Private label / Generic EBITDA 1,972 Mio 25%
(excl 24|7 operating cost &
sales
ESOP)
Margin
8.4%
----- End of picture text -----

==> picture [81 x 61] intentionally omitted <==

Clinical Updates and New Initiatives

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

At Apollo Chennai, over 500 robotic cardiac surgeries were successfully performed from June 2019 to October 2024, highest number for a single center in India
At Apollo Bangalore, A robotic knee replacement surgery was successfully performed on a 17-year-old boy (the youngest reported case in the world), struggling with knee pain due to severe Avascular Necrosis.

Hospitals

India’s first new-generation Allegra Transcatheter Aortic Valve Implantation (TAVI) was successfully performed on a 78-year-old male patient with prior valve replacement surgery at Apollo Chennai.
At Apollo JH, Hyderabad a record 25 complex Asleep Deep Brain Stimulation surgeries performed in 24 days

Clinical Achievements & Updates

At Apollo Kolkata rare and complex kidney condition, malignancy in a cross-fused ectopic kidney was successfully treated in a 60-year-old male patient, using robotic-assisted surgery. This was the first of its kind procedure in India.
Successfully performed a complex hip replacement surgery on a Kenyan teenager who endured four years of pain and mobility issues due to a failed femur surgery after a car accident. The botched procedure led to Leg Length Discrepancy (LLD) and chronic limping, worsened by weight gain.

AHLL

Expansion of test-menu to include component resolved diagnostics (CRD) panel testing for allergy, protein microarray based testing for food intolerance, X-Pert MTB/XDR testing for Tuberculosis, oligoclonal bands IGG (CSF) testing for neurological disorders and immunofixation electrophoresis (IFE) testing for plasma cell disorders.
Started mental health as a new service line in Marathahalli, Bangalore in association with 1to1help.net, enhancing our psychology & psychiatry service offerings. Also extended Pro Health to Diabetes & Cancer Screening through exclusive package creation across Clinics.
Running ML driven targeted marketed campaigns to improve user conversion for hospitals
Strengthening existing cross pollination journeys & Circle value proposition for Diagnostics users

Apollo HealthCo

Observing improvement in transacting customers (1.2x+) and higher conversion of our portfolio customers
Strengthening customer value proposition by offering 19 minutes medicine delivery proposition in 4 cities and strengthening the omnichannel Circle loyalty program thereby improving the quality of customer acquisition
Obtained the IRDAI corporate agency license on 9th Dec 24 to distribute retail insurance products. Expect to start sourcing business by Q4 exit.

==> picture [1152 x 6] intentionally omitted <==

Consolidated Financials

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Consolidated Financials Q3FY25

		Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol 27,850 3,895 23,524 55,269 6,706 342 1,972 9,020 24.1% 8.8% 8.4% 16.3% -1,137 -1,137 -268 -268 6,706 342 566 7,615 24.1% 8.8% 2.4% 13.8% 5,296 37 436 5,769 19.0% 1.0% 1.9% 10.4% 5,132 -90 321 5,362 18.4% - 1.4% 9.7% 3,483 -80 321 3,723 24,636 3,377 20,493 48,506 5,860 259 1,575 7,694 23.8% 7.7% 7.7% 15.9% -1,414 -1,414 -142 -142 5,860 259 19 6,137 23.8% 7.7% 0.1% 12.7% 4,582 -11 -104 4,467 18.6% - - 9.2% 4,104 -195 -275 3,633 16.7% - - 7.5% 2,872 -143 -276 2,453 13% 15% 15% 14% 14% 32% 2952% 24% 21% - - 52%	Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol 27,850 3,895 23,524 55,269 6,706 342 1,972 9,020 24.1% 8.8% 8.4% 16.3% -1,137 -1,137 -268 -268 6,706 342 566 7,615 24.1% 8.8% 2.4% 13.8% 5,296 37 436 5,769 19.0% 1.0% 1.9% 10.4% 5,132 -90 321 5,362 18.4% - 1.4% 9.7% 3,483 -80 321 3,723 24,636 3,377 20,493 48,506 5,860 259 1,575 7,694 23.8% 7.7% 7.7% 15.9% -1,414 -1,414 -142 -142 5,860 259 19 6,137 23.8% 7.7% 0.1% 12.7% 4,582 -11 -104 4,467 18.6% - - 9.2% 4,104 -195 -275 3,633 16.7% - - 7.5% 2,872 -143 -276 2,453 13% 15% 15% 14% 14% 32% 2952% 24% 21% - - 52%
` Mio		Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol
	Total Revenues	27,850 3,895 23,524 55,269
	**EBITDA (Pre 24	7 Cost)**	6,706 342 1,972 9,020
	margin (%)	24.1% 8.8% 8.4% 16.3%
	24/7 Operating Cost	-1,137 -1,137
	ESOP(Non Cash expense)	-268 -268
2	EBITDA	6,706 342 566 7,615
Q3FY5	margin (%)	24.1% 8.8% 2.4% 13.8%
	EBIT	5,296 37 436 5,769
	margin (%)	19.0% 1.0% 1.9% 10.4%
	PBT	5,132 -90 321 5,362
	margin (%)	18.4% - 1.4% 9.7%
	PAT(Reported)	3,483 -80 321 3,723

	Total Revenues	24,636 3,377 20,493 48,506
	**EBITDA (Pre 24	7 Cost)**	5,860 259 1,575 7,694
	margin (%)	23.8% 7.7% 7.7% 15.9%
	24/7 Operating Cost	-1,414 -1,414
	ESOP(Non Cash expense)	-142 -142
2	EBITDA	5,860 259 19 6,137
Q3FY4	margin (%)	23.8% 7.7% 0.1% 12.7%
	EBIT	4,582 -11 -104 4,467
	margin (%)	18.6% - - 9.2%
	PBT	4,104 -195 -275 3,633
	margin (%)	16.7% - - 7.5%
	PAT(Reported)	2,872 -143 -276 2,453
YOY Growth
Revenue		13% 15% 15%	14%
EBITDA		14% 32% 2952%	24%
PAT		21% - -	52%

==> picture [49 x 56] intentionally omitted <==

(` mio)

==> picture [13 x 13] intentionally omitted <==

Overall Consolidated Revenue grew by 14% to ` 55,269 mio.

EBITDA grew by 24% to ` 7,615 mio.

Consolidated PAT grew by 52% to ` 3,723 mio.

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Consolidated Financials YTD Dec24

		Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol 83,255 11,596 67,167 162,018 20,144 1,065 5,567 26,775 24.2% 9.2% 8.3% 16.5% -3,634 -3,634 -621 -621 20,144 1,065 1,312 22,521 24.2% 9.2% 2.0% 13.9% 15,977 181 897 17,056 19.2% 1.6% 1.3% 10.5% 15,122 -268 382 15,236 18.2% - 0.6% 9.4% 10,409 -228 382 10,563 73,045 10,107 58,002 141,153 17,627 809 4,635 23,071 24.1% 8.0% 8.0% 16.3% -4,784 -4,784 -785 -785 17,627 809 -934 17,502 24.1% 8.0% - 12.4% 13,915 -83 -1,303 12,529 19.1% - - 8.9% 12,458 -558 -1,777 10,123 17.1% - - 7.2% 8,648 -420 -1,779 6,448 14% 15% 16% 15% 14% 32% - 29% 20% - - 64%	Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol 83,255 11,596 67,167 162,018 20,144 1,065 5,567 26,775 24.2% 9.2% 8.3% 16.5% -3,634 -3,634 -621 -621 20,144 1,065 1,312 22,521 24.2% 9.2% 2.0% 13.9% 15,977 181 897 17,056 19.2% 1.6% 1.3% 10.5% 15,122 -268 382 15,236 18.2% - 0.6% 9.4% 10,409 -228 382 10,563 73,045 10,107 58,002 141,153 17,627 809 4,635 23,071 24.1% 8.0% 8.0% 16.3% -4,784 -4,784 -785 -785 17,627 809 -934 17,502 24.1% 8.0% - 12.4% 13,915 -83 -1,303 12,529 19.1% - - 8.9% 12,458 -558 -1,777 10,123 17.1% - - 7.2% 8,648 -420 -1,779 6,448 14% 15% 16% 15% 14% 32% - 29% 20% - - 64%
` Mio		Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol
	Total Revenues	83,255 11,596 67,167 162,018
	**EBITDA (Pre 24	7 Cost)**	20,144 1,065 5,567 26,775
	margin (%)	24.2% 9.2% 8.3% 16.5%
	24/7 Operating Cost	-3,634 -3,634
	ESOP(Non Cash expense)	-621 -621
YTD Dec24	EBITDA	20,144 1,065 1,312 22,521
	margin (%)	24.2% 9.2% 2.0% 13.9%
	EBIT	15,977 181 897 17,056
	margin (%)	19.2% 1.6% 1.3% 10.5%
	PBT	15,122 -268 382 15,236
	margin (%)	18.2% - 0.6% 9.4%
	PAT(Reported)	10,409 -228 382 10,563

	Total Revenues	73,045 10,107 58,002 141,153
	**EBITDA (Pre 24	7 Cost)**	17,627 809 4,635 23,071
	margin (%)	24.1% 8.0% 8.0% 16.3%
	24/7 Operating Cost	-4,784 -4,784
	ESOP(Non Cash expense)	-785 -785
	EBITDA	17,627 809 -934 17,502
YTD Dec23	margin (%)	24.1% 8.0% - 12.4%
	EBIT	13,915 -83 -1,303 12,529
	margin (%)	19.1% - - 8.9%
	PBT	12,458 -558 -1,777 10,123
	margin (%)	17.1% - - 7.2%
	PAT(Reported)	8,648 -420 -1,779 6,448
YOY Growth
Revenue		14% 15% 16%	15%
EBITDA		14% 32% -	29%
PAT		20% - -	64%

==> picture [49 x 56] intentionally omitted <==

(` mio)

==> picture [13 x 13] intentionally omitted <==

==> picture [431 x 458] intentionally omitted <==

----- Start of picture text -----

Overall Consolidated Revenue grew by 15% to 162,018 mio. EBITDA grew by 29% to 22,521 mio.
PAT grew by 64% to 10,563 mio. HCS Health Co AHLL Gross Debt 21,893 2,995 2,568 Cash & Cash 26,439 427 1,963 Equivalents* Net Debt -4,546 2,567 605 *Includes investments in Liquid funds and FDs of 23,785 mio.
Consol Gross
27,455
Debt
Consol Net
-1,374
Debt
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

Healthcare Services Hospitals

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Healthcare Services Financials

==> picture [664 x 415] intentionally omitted <==

----- Start of picture text -----

YTD YTD
` Mio Q3FY25 Q3FY24 YoY YoY
Dec24 Dec23
No of Hospitals 45 45 45 45
Operating beds 7,996 7,911 1% 7,996 7,911 1%
Occupancy 68% 66% 69% 65%
IP Discharges 150,986 143,273 5% 457,816 423,474 8%
ALOS 3.29 3.34 -1% 3.33 3.33 0%
ARPOB 60,839 56,368 8% 59,634 56,823 5%
Revenue 27,850 24,636 13% 83,255 73,045 14%
EBITDA (Post Ind AS 116) 6,706 5,860 14% 20,144 17,627 14%
margin (%) 24.1% 23.8% 30 bps 24.2% 24.1% 6 bps
EBIT 5,296 4,582 16% 15,977 13,915 15%
margin (%) 19.0% 18.6% 42 bps 19.2% 19.1% 14 bps
PBT 5,132 4,104 25% 15,122 12,458 21%
PAT 3,483 2,872 21% 10,409 8,648 20%
Margin 12.5% 11.7% 85 bps 12.5% 11.8% 66 bps
----- End of picture text -----

==> picture [49 x 56] intentionally omitted <==

(` mio)

==> picture [13 x 13] intentionally omitted <==

Healthcare Services Revenue grew by 13% in Q3FY25

(Inpatient Volume grew by 5% ; Price & case mix of 8%)

Focus on higher growth in CONGO-T specialties (10% YoY volume growth) aided higher revenue realisation in Q3FY25.

Occupancy for Q3FY25 at 68% vs 66% in Q3FY24

Average Revenue per In patient grew by 7% to `162,957

Capital employed ` 73,444 ROCE 29% (ROCE – YTD Dec24)

capital employed excludes CWIP of ` 10,952 mio toward new projects under development

==> picture [1152 x 6] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

In atients Revenue Mix YTD Dec2 p 4

==> picture [1014 x 586] intentionally omitted <==

----- Start of picture text -----

IPS
Paed
Transplts
Uro
3% PSU & Govt
3% Cardio
6%
Nephro
3%
18%
10%
4% Self Pay
Obs&Gynac
4%
Gen Surg
4% 40%
Inpatient Inpatient
7%
Others Specialty Mix Payor Mix
17% Onco
10%
Internal Med
10%
44%
6%
Gastro
10%
Neuro
Insurance
Ortho
----- End of picture text -----*

Oncology includes Radiotherapy and Chemotherapy

==> picture [49 x 56] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Healthcare Services : O erational Sna shot p p

==> picture [13 x 13] intentionally omitted <==

==> picture [422 x 324] intentionally omitted <==

----- Start of picture text -----

Metros
Mumbai, Kolkata and Delhi
Ahmedabad, Bhubaneshwar, Lucknow,
Indore, Guwahati, Madurai, Trichy,
Karaikudi.
Delhi
Lucknow Bilaspur
Indore
Ahmedabad
Guwahati
Rourkela
Kolkata
Bhubaneshwar
----- End of picture text -----

==> picture [447 x 195] intentionally omitted <==

----- Start of picture text -----

YTD Dec 24 Metros Non Metros
Operating
4,549 3,447
Beds
^ARPOB is net of fees paid to fee for service doctors which is Occupancy 71% 66%
netted off in the reported revenues
ARPOB [^] 72,512 41,668
ROCE 31% 28%
----- End of picture text -----

Metros : Chennai, Hyderabad, Bangalore, Mumbai, Kolkata and Delhi

Non Metros (includes Tier1 & Tier2 cities)

Ahmedabad, Bhubaneshwar, Lucknow, Indore, Guwahati, Madurai, Trichy, Nellore,Vizag, Kakinada, Mysore, Nashik, Bilaspur, Rourkela, Karimnagar, Karur and Karaikudi.

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

==> picture [267 x 251] intentionally omitted <==

----- Start of picture text -----

Nashik
Karimnagar
Mumbai
Hyderabad
Kakinada
Bangalore Nellore
Mysore
Chennai
Karur
Madurai
Trichy
Karaikudi
----- End of picture text -----

==> picture [572 x 217] intentionally omitted <==

----- Start of picture text -----

Pan India
Q3FY25 Q3FY24 YoY YTD Dec24 YTD Dec23 YoY
Operating Beds 7,996 7,911 1.1% 7,996 7,911 1.1%
Bed Occupancy Rate (%) 68% 66% 69% 65%
Inpatient volume 150,986 143,273 5.4% 457,816 423,474 8.1%
Outpatient volume [(1)] 561,652 457,198 22.8% 1,672,573 1,442,877 15.9%
Inpatient ALOS (days) 3.29 3.34 -1.4% 3.33 3.33 -0.2%
Total Net Revenue ( mio) [(2)] 30,315 27,075 12.0% 91,030 80,453 13.1% Avg revenue per In Patient 162,957 152,007 7.2% 160,197 151,726 5.6% ARPOB ( /day) [(^)] 60,839 56,368 7.9% 59,634 56,823 4.9%
----- End of picture text -----

==> picture [142 x 72] intentionally omitted <==

----- Start of picture text -----

Rourkela
Kolkata
Bhubaneshwar
Vishakhapatnam
----- End of picture text -----

1 Outpatient Volume represents New Registrations only |2Revenue will differ from the consolidated revenues as this includes Delhi which is not consolidated under Ind AS 116 due to joint control

==> picture [1152 x 6] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

Tamil Nadu Region

==> picture [81 x 61] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore

==> picture [149 x 168] intentionally omitted <==

==> picture [293 x 291] intentionally omitted <==

----- Start of picture text -----

Nellore
Nellore
Chennai
Trichy
MaduraiKarur
Madurai
Karaikudi
----- End of picture text -----

==> picture [599 x 228] intentionally omitted <==

----- Start of picture text -----

Tamil Nadu Region
Q3FY25 Q3FY24 YoY YTD Dec24 YTD Dec23 YoY
Operating Beds 2,039 2,022 0.8% 2,039 2,022 0.8%
Bed Occupancy Rate (%) 64% 66% 64% 63%
Inpatient volume 38,561 38,398 0.4% 115,360 111,512 3.5%
(1)
Outpatient volume 153,935 141,539 8.8% 459,012 436,827 5.1%
Inpatient ALOS (days) 3.11 3.21 -3.1% 3.12 3.14 -0.8%
Total Net Revenue ( mio) 9,253 8,564 8.0% 27,827 25,388 9.6% Avg revenue per In Patient 186,682 172,307 8.3% 184,546 172,652 6.9% (^) ARPOB ( /day) 77,084 69,412 11.1% 77,308 72,402 6.8%
----- End of picture text -----

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

==> picture [106 x 28] intentionally omitted <==

----- Start of picture text -----

YTD Dec24
----- End of picture text -----

==> picture [524 x 149] intentionally omitted <==

----- Start of picture text -----

Metro Non Metro
Operating Operating
1,354 685
Beds Beds
Occupancy 66% Occupancy 60%
ARPOB [^] 92,808 ARPOB [^] 43,696
----- End of picture text -----

Expansion Plan

==> picture [345 x 90] intentionally omitted <==

----- Start of picture text -----

Total Census
Location Nature
Beds Beds
OMR, Chennai Greenfield 600 500
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

AP Telan ana Re ion , g g

Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada

==> picture [149 x 168] intentionally omitted <==

==> picture [289 x 288] intentionally omitted <==

----- Start of picture text -----

Vishakhapatnam
Kakinada
Karimnagar
Hyderabad
----- End of picture text -----

==> picture [49 x 56] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

==> picture [600 x 227] intentionally omitted <==

----- Start of picture text -----

AP, Telangana Region
Q3FY25 Q3FY24 YoY YTD Dec24 YTD Dec23 YoY
Operating Beds 1,240 1,270 -2.4% 1,240 1,270 -2.4%
Bed Occupancy Rate (%) 66% 57% 68% 57%
Inpatient volume 22,035 19,099 15.4% 65,842 58,103 13.3%
(1)
Outpatient volume 78,971 54,721 44.3% 229,072 164,251 39.5%
Inpatient ALOS (days) 3.40 3.46 -1.7% 3.51 3.43 2.3%
Total Net Revenue ( mio) 4,722 3,811 23.9% 13,651 11,321 20.6% Avg revenue per In Patient 180,753 166,348 8.7% 173,765 162,070 7.2% (^) ARPOB ( /day) 63,013 57,660 9.3% 59,070 56,775 4.0%
----- End of picture text -----

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

==> picture [106 x 28] intentionally omitted <==

----- Start of picture text -----

YTD Dec24
----- End of picture text -----

==> picture [524 x 149] intentionally omitted <==

----- Start of picture text -----

Metro Non Metro
Operating Operating
759 481
Beds Beds
Occupancy 70% Occupancy 65%
ARPOB [^] 68,643 ARPOB [^] 42,807
----- End of picture text -----

==> picture [514 x 173] intentionally omitted <==

----- Start of picture text -----

Expansion Plan
Total Census
Location Nature
Beds Beds
Greenfield - Asset
Gachibowli, Hyderabad 375 300
Light
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Karnataka Re ion g

Metro:- Bangalore; Non Metro:- Mysore

==> picture [149 x 168] intentionally omitted <==

==> picture [287 x 288] intentionally omitted <==

----- Start of picture text -----

Bangalore
Mysore
----- End of picture text -----

==> picture [49 x 56] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

==> picture [599 x 227] intentionally omitted <==

----- Start of picture text -----

Karnataka Region
Q3FY25 Q3FY24 YoY YTD Dec24 YTD Dec23 YoY
Operating Beds 772 750 2.9% 772 750 2.9%
Bed Occupancy Rate (%) 71% 67% 75% 66%
Inpatient volume 16,991 16,255 4.5% 53,221 48,222 10.4%
(1)
Outpatient volume 72,056 51,299 40.5% 204,319 154,258 32.5%
Inpatient ALOS (days) 2.97 2.83 4.9% 2.99 2.83 5.8%
Total Net Revenue ( mio) 3,310 2,839 16.6% 9,870 8,443 16.9% Avg revenue per In Patient 162,086 147,198 10.1% 155,955 147,363 5.8% (^) ARPOB ( /day) 65,513 61,611 6.3% 61,956 61,903 0.1%
----- End of picture text -----

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

==> picture [106 x 28] intentionally omitted <==

----- Start of picture text -----

YTD Dec24
----- End of picture text -----

==> picture [524 x 177] intentionally omitted <==

----- Start of picture text -----

Metro Non Metro
Operating Operating
559 213
Beds Beds
Occupancy 76% Occupancy 72%
ARPOB [^] 68,241 ARPOB [^] 44,571
^ ARPOB is net of fees paid to fee for service doctors and
is netted off in the reported revenues
----- End of picture text -----

Expansion Plan

==> picture [376 x 85] intentionally omitted <==

----- Start of picture text -----

Total Census
Location Nature
Beds Beds
Malleswaram & Mysore
Brownfield 140 125
Expansion
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Eastern Re ion g

==> picture [13 x 13] intentionally omitted <==

Metro:- Kolkata; Non Metro:- Guwahati, Bhubaneshwar, Bilaspur and Rourkela

==> picture [149 x 168] intentionally omitted <==

==> picture [292 x 288] intentionally omitted <==

----- Start of picture text -----

Guwahati
Kolkata
Bilaspur
Rourkela
Bhubaneshwar
----- End of picture text -----

==> picture [600 x 227] intentionally omitted <==

----- Start of picture text -----

Eastern Region
Q3FY25 Q3FY24 YoY YTD Dec24 YTD Dec23 YoY
Operating Beds 1,867 1,812 3.0% 1,867 1,812 3.0%
Bed Occupancy Rate (%) 72% 73% 75% 74%
Inpatient volume 32,780 31,187 5.1% 101,156 93,479 8.2%
(1)
Outpatient volume 108,894 94,961 14.7% 345,080 308,816 11.7%
Inpatient ALOS (days) 3.79 3.90 -2.8% 3.82 3.93 -2.9%
Total Net Revenue ( mio) 5,770 5,322 8.4% 17,752 15,858 11.9% Avg revenue per In Patient 140,979 137,172 2.8% 139,279 134,499 3.6% (^) ARPOB ( /day) 46,485 43,778 6.2% 45,965 43,162 6.5%
----- End of picture text -----

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

==> picture [106 x 28] intentionally omitted <==

----- Start of picture text -----

YTD Dec24
----- End of picture text -----

==> picture [523 x 177] intentionally omitted <==

----- Start of picture text -----

Metro Non Metro
Operating Operating
736 1,131
Beds Beds
Occupancy 81% Occupancy 71%
ARPOB [^] 60,720 ARPOB [^] 35,053
^ ARPOB is net of fees paid to fee for service doctors and
is netted off in the reported revenues
----- End of picture text -----

Expansion Plan

==> picture [347 x 83] intentionally omitted <==

----- Start of picture text -----

Total Census
Location Nature
Beds Beds
Sonarpur, Hospital Asset
270 220
Kolkata Acquisition
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Western Re ion g

Metro:- Navi Mumbai; Non Metro:- Nashik and Ahmedabad

==> picture [149 x 168] intentionally omitted <==

==> picture [292 x 288] intentionally omitted <==

----- Start of picture text -----

Ahmedabad
Nashik
Mumbai
----- End of picture text -----

==> picture [49 x 56] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

==> picture [600 x 228] intentionally omitted <==

----- Start of picture text -----

Western Region
Q3FY25 Q3FY24 YoY YTD Dec24 YTD Dec23 YoY
Operating Beds 876 861 1.7% 876 861 1.7%
Bed Occupancy Rate (%) 57% 57% 59% 55%
Inpatient volume 13,109 13,344 -1.8% 40,195 37,523 7.1%
(1)
Outpatient volume 58,919 46,738 26.1% 170,957 158,811 7.6%
Inpatient ALOS (days) 3.50 3.36 4.3% 3.55 3.45 2.9%
Total Net Revenue ( mio) 2,355 2,105 11.9% 6,970 6,153 13.3% Avg revenue per In Patient 148,313 126,197 17.5% 142,479 131,622 8.2% (^) ARPOB ( /day) 51,325 46,994 9.2% 48,873 47,572 2.7%
----- End of picture text -----

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

==> picture [106 x 28] intentionally omitted <==

----- Start of picture text -----

YTD Dec24
----- End of picture text -----

==> picture [524 x 149] intentionally omitted <==

----- Start of picture text -----

Metro Non Metro
Operating Operating
392 484
Beds Beds
Occupancy 65% Occupancy 54%
ARPOB [^] 55,895 ARPOB [^] 42,007
----- End of picture text -----

Expansion Plan

==> picture [365 x 107] intentionally omitted <==

----- Start of picture text -----

Total Census
Location Nature
Beds Beds
Hospital Asset
Royal Mudhol Pune 400 325
Acquisition
Worli, Mumbai Greenfield 575 500
Total 975 825
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Northern Re ion g

Metro:- Delhi; Non Metro:- Lucknow and Indore

==> picture [149 x 168] intentionally omitted <==

==> picture [292 x 288] intentionally omitted <==

----- Start of picture text -----

Delhi
Lucknow
IndoreIndore
----- End of picture text -----

==> picture [49 x 56] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

==> picture [600 x 228] intentionally omitted <==

----- Start of picture text -----

Northern Region
Q3FY25 Q3FY24 YoY YTD Dec24 YTD Dec23 YoY
Operating Beds 1,202 1,196 0.5% 1,202 1,196 0.5%
Bed Occupancy Rate (%) 74% 70% 74% 69%
Inpatient volume 27,510 24,990 10.1% 82,042 74,635 9.9%
(1)
Outpatient volume 88,877 67,940 30.8% 264,133 219,914 20.1%
Inpatient ALOS (days) 2.96 3.07 -3.4% 2.97 3.06 -2.9%
Total Net Revenue ( mio) 4,905 4,435 10.6% 14,959 13,290 12.6% Avg revenue per In Patient 152,072 151,103 0.6% 155,038 150,875 2.8% (^) ARPOB ( /day) 60,219 57,888 4.0% 61,430 58,232 5.5%
----- End of picture text -----

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

==> picture [106 x 28] intentionally omitted <==

----- Start of picture text -----

YTD Dec24
----- End of picture text -----

==> picture [524 x 149] intentionally omitted <==

----- Start of picture text -----

Metro Non Metro
Operating Operating
749 453
Beds Beds
Occupancy 73% Occupancy 75%
ARPOB [^] 67,010 ARPOB [^] 52,373
----- End of picture text -----

==> picture [520 x 183] intentionally omitted <==

----- Start of picture text -----

Expansion Plan
Total Census
Location Nature
Beds Beds
Hospital Asset
Gurgaon 510 420
Acquisition
Varanasi Greenfield 400 300
Lucknow (2) Brownfield 200 160
Defence Colony, Delhi Brownfield 42 27
Total 1152 907
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Healthcare Services: Ex ansion Plan p

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

Location Nature Total Beds Census Beds Project Cost (in Crs) Balance Project Cost (in Crs)	Location Nature Total Beds Census Beds Project Cost (in Crs) Balance Project Cost (in Crs)	Location Nature Total Beds Census Beds Project Cost (in Crs) Balance Project Cost (in Crs)	Location Nature Total Beds Census Beds Project Cost (in Crs) Balance Project Cost (in Crs)	Location Nature Total Beds Census Beds Project Cost (in Crs) Balance Project Cost (in Crs)

Expected commissioning: FY26
Royal Mudhol Pune Hospital Asset Acquisition	400	325	₹ 630	₹ 265
Sonarpur,Kolkata Hospital Asset Acquisition Gachibowli,Hyderabad Greenfield - Asset Light Gurgaon Hospital Asset Acquisition	270 375 510	220 300 420	₹ 310 ₹ 515 ₹ 1,190	₹ 150 ₹ 425 ₹ 615
Malleswaram & Mysore Expansion Brownfield	140	125	₹ 170	₹ 165
Defence Colony,Delhi Brownfield	42	27	₹ 65	₹ 35
	1,737	1,417	₹ 2,880	₹ 1,655

Expected commissioning: In next 3 - 4years
OMR,Chennai Greenfield	600	500	₹ 945	₹ 685
Varanasi Greenfield	400	300	₹ 640	₹ 540
Worli,Mumbai Greenfield	575	500	₹ 1,315	₹ 1,225
Lucknow(2) Brownfield	200	160	₹ 320	₹ 235
	1,775	1,460	₹ 3,220	₹ 2,685

Total	3,512	2,877	₹ 6,100	₹ 4,340

Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros

==> picture [1152 x 6] intentionally omitted <==

Diagnostics & Retail Health Apollo Health & Lifestyle Ltd

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Executive Summar y

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

Primary Care

==> picture [74 x 38] intentionally omitted <==

==> picture [69 x 43] intentionally omitted <==

==> picture [87 x 35] intentionally omitted <==

==> picture [81 x 34] intentionally omitted <==

Core revenues of Primary Care grew by ~14% YoY in 9M’FY25, as a result of redesigning of health check plans and higher contribution from corporate segment
Improvement in margin profile as a result of various cost saving initiatives
Preventive Health-checks volume grew by ~15% YoY in 9M’FY25
Plan to expand service offerings in Core Clinics to address future demands
7 New Dialysis Clinics launched in 9M’FY25
Diagnostics
Wellness segment volume grew by ~36% YoY in 9M’FY25 & contributed to ~18% of Diagnostics revenue (vs ~15% in 9M’FY24)
Continuous improvement in EBITDA margin since last 8 quarters (~5% in Q3’23 vs ~10% in Q3’25)
Test-menu expansion to include CRD panel testing for allergy, microarray based testing for food intolerance, X-Pert MTB/XDR testing for TB and oligoclonal bands IGG testing for neurological disorders. Testmenu expected to cross 2,400+ tests by the end of FY25

Specialty Care

==> picture [57 x 51] intentionally omitted <==

==> picture [93 x 38] intentionally omitted <==

==> picture [79 x 46] intentionally omitted <==

Spectra: ~18% YoY revenue growth in 9M’FY25 driven by operationalization of renovated centers
Cradle: ~15% YoY revenue growth in 9M’FY25. An upcoming marquee project across strategic location, currently in developmental phase
Fertility: ~19% YoY revenue growth in 9M’FY25 due to improved footfall

==> picture [1152 x 6] intentionally omitted <==

(` mio)

AHLL Financials FY2 Q3 5

==> picture [14 x 13] intentionally omitted <==

==> picture [728 x 380] intentionally omitted <==

----- Start of picture text -----

Corporate / Intra
Primary Care Diagnostics Specialty Care AHLL
Group
Revenue 1,069 1,212 1,724 -110 3,895
EBITDA 193 116 183 -150 342
Q3FY25 margin (%) 18.1% 9.6% 10.6% - 8.8%
EBIT 123 71 -8 -149 37
PAT 128 66 -151 -161 -117
Revenue 913 1,122 1,523 -180 3,377
EBITDA 111 112 193 -157 259
Q3FY24 margin (%) 12.2% 10.0% 12.7% - 7.7%
EBIT 44 79 26 -160 -11
PAT 11 71 -111 -180 -208
Growth
-
Revenue 17% 8% 13% 15%
-
EBITDA 74% 4% -5% 32%
----- End of picture text -----

==> picture [49 x 56] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

AHLL Revenues grew by 15% YoY in Q3’ FY25; primarily attributed to maturing network

Primary care Revenue and EBITDA grew by 17% and 74% YoY in Q3’FY25 respectively due to redesigning of health check plans & cost savings initiatives

Specialty care revenue grew by 13% YoY in Q3’FY25 due to improving footfalls. Growth slightly impacted in Q3 due to prolonged festive season

==> picture [974 x 117] intentionally omitted <==

----- Start of picture text -----

Primary Clinics Sugar Clinics Dental Clinics Dialysis Diagnostics Spectra [1] Birthing Centers [1] Total
Network
263 74 200 134 2,324 23 32 3,050
Footfalls /
2,546 477 221 2,312 14,420 84 102 20,210
Day
Gross ARPP 2,260 3,194 7,016 1,625 811 101,089 84,505 1,953
----- End of picture text -----*

==> picture [1152 x 6] intentionally omitted <==

(` mio)

AHLL Financials YTD Dec2 4

==> picture [14 x 13] intentionally omitted <==

==> picture [728 x 404] intentionally omitted <==

----- Start of picture text -----

Corporate / Intra
Primary Care Diagnostics Specialty Care AHLL
Group
Revenue 3,127 3,721 5,257 -510 11,596
EBITDA 576 407 576 -494 1,065
YTD Dec24 margin (%) 18.4% 10.9% 11.0% - 9.2%
EBIT 363 285 24 -490 181
PAT 291 266 -207 -681 -331
Revenue 2,717 3,436 4,490 -536 10,107
EBITDA 418 336 551 -496 809
YTD Dec23 margin (%) 15.4% 9.8% 12.3% - 8.0%
EBIT 218 237 -33 -505 -83
PAT 116 214 -374 -566 -611
Growth
-
Revenue 15% 8% 17% 15%
-
EBITDA 38% 21% 5% 32%
----- End of picture text -----

==> picture [49 x 56] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

AHLL Revenues grew by 15% YoY in YTD Dec 24; primarily attributed to maturing network

Diagnostics revenue and EBITDA grew by 8% and 21% YoY in YTD Dec24 respectively due to increase in productivity

Primary care revenue and EBITDA grew by 15% and 38% YoY in YTD Dec 24 respectively due to redesigning of health check plans & cost savings initiatives

Specialty care revenue grew by 17% YoY in YTD Dec24 due to improving footfalls.

==> picture [974 x 117] intentionally omitted <==

----- Start of picture text -----

Primary Clinics Sugar Clinics Dental Clinics Dialysis Diagnostics Spectra [1] Birthing Centers [1] Total
Network
263 74 200 134 2,324 23 32 3,050
Footfalls /
2,546 501 221 2,260 14,774 86 115 22,957
Day
Gross ARPP 2,260 3,200 7,043 1,621 811 101,535 82,201 1,947
----- End of picture text -----*

==> picture [1152 x 6] intentionally omitted <==

2727

Diagnostics : Key Parameters

==> picture [81 x 61] intentionally omitted <==

Gross Revenue (INR Mn)

==> picture [441 x 205] intentionally omitted <==

----- Start of picture text -----

1,345
1,122 1,169 1,164 1,212
1
Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25
Gross Revenue (Rs. Mn)
----- End of picture text -----

Avg. Footfalls per day & Avg. gross realization per patient (INR)[*]

==> picture [448 x 191] intentionally omitted <==

----- Start of picture text -----

827
806 811
731 731
16,205
15,143
14,420
14,753 13,697
Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25
Footfalls / Day Gross ARPV (Rs.)
----- End of picture text -----*

1. EBITDA post IND AS 116;

Footfalls and ARPV for diagnostics represent outpatient / external business

EBITDA (INR Mn)[1]

==> picture [406 x 208] intentionally omitted <==

----- Start of picture text -----

14%
13%
10%
9% 10%
181
168
112 110 116
Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25
EBITDA (Rs. Mn) EBITDA Margin %
----- End of picture text -----

Network Growth – Collection Centers[#]

==> picture [459 x 238] intentionally omitted <==

----- Start of picture text -----

+180
2,330
2,263
2,221
2,102
2,041
Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25
# Rationalized the commission structure for collection centers,
resulting in reduction of centers in Q2 FY25. Achieved an
----- End of picture text -----

improvement in EBITDA margin and developed unit economics model to drive sustainable, profitable growth.

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

Operational footprint (as of Dec 31, 2024)

==> picture [140 x 101] intentionally omitted <==

----- Start of picture text -----

~330+
~330+
Cities
Cities presence
presence
----- End of picture text -----

==> picture [140 x 100] intentionally omitted <==

----- Start of picture text -----

103
Labs
----- End of picture text -----

==> picture [140 x 226] intentionally omitted <==

----- Start of picture text -----

2,221+
Collection Centres
3,000+
Pick-up Points
(PUPs)
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

Digital Health & Pharmacy Distribution Apollo HealthCo

==> picture [1152 x 6] intentionally omitted <==

==> picture [14 x 13] intentionally omitted <==

’ - India s Largest Omni Channel Healthcare Platform

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

==> picture [1135 x 577] intentionally omitted <==

----- Start of picture text -----

Apollo 247 Digital Platform Apollo Pharmacy Platform
6,360 Stores ~16.4%
Omni Private
~38 Mn+ Registrations Added - YTD 334
label / generics
Chandigarh: 5
mix
Closed – YTD 4 - YTD Dec24
Himachal Pradesh: 6
Uttarakhand: 35
~10,100 Doctors Punjab: 65 New Delhi: 122 Net – YTD 330
Haryana: 99 Uttar Pradesh 202
Assam: 36
Bihar: 28
Daily Active Users 7.8 Lakh
Telangana: 819
Rajasthan: 106
Daily Consultations 14,200+ Goa: 47
Karnataka: 884
Daily Medicine Orders 54,000+
Tripura: 7
Daily Sample Collections ~2,500 Kerala: 104 Jharkhand : 30
West Bengal: 810
Madhya Pradesh: 28
Orissa: 174
Gujarat: 220
Chhattisgarh: 74
Maharashtra: 258 Telangana: 849
Goa: 53
Andhra Pradesh: 914
Karnataka: 919
Virtual Doctor Consultation
Online Booking : Hospitals & Diagnostics
Puducherry: 22
Kerala: 121
Online Medicine delivery Insurance Tamil Nadu: 1171 Andaman: 6
Patient e-health records
Condition management
30
© 2024 Apollo Hospitals Enterprise Ltd, All Rights Reserved
----- End of picture text -----

==> picture [1152 x 6] intentionally omitted <==

(` mio)

==> picture [81 x 61] intentionally omitted <==

A ollo HealthCo Financials FY2 p Q3 5

` Mio		Offline Pharmacy Distribution Online Pharmacy Distribution & Apollo 247 Total HealthCo
	Total Revenues	20,786 2,738 23,524
	**EBITDA (Pre 24	7 Cost)**
	margin (%)	7.7% 13.8% 8.4%
	24/7 Operating Cost	-1,137 -1,137
3FY25	ESOP(Non Cash expense)	-268 -268
Q	EBITDA margin (%)	1,593 -1,027 566 7.7% - 2.4%

	EBIT PBT PAT(Reported)	436 321 321


	Total Revenues **EBITDA (Pre 24	7 Cost) margin (%)** 24/7 Operating Cost ESOP(Non Cash expense)




3FY24
Q	EBITDA	1,341 -1,322 19
	margin (%)	7.3% - 0.1%
	EBIT PBT PAT(Reported)	-104 -275 -276



Revenue		14% 22% 15%
EBITDA(Pre 24	7 Cost)

Excluding 24|7 operating Cost and ESOP Non-Cash Charge

**Digital Cash loss* (in Mn)**

**Healthco Cash profit* (in Mn)**

==> picture [499 x 71] intentionally omitted <==

----- Start of picture text -----

Q3'FY24 Q2'FY25 Q3'FY25
5X 835
677
-758 161
-854
-1,184
36% Q3'FY24 Q2'FY25 Q3'FY25
----- End of picture text -----

*Cash loss/profit is EBITDA post Ind As excluding ESOP expense

==> picture [13 x 13] intentionally omitted <==

Healthco (Q3’ FY25 vs Q3’ FY24);

o 15% growth in revenue in Q3’ FY25 vs Q3’ FY24

PAT positive in Q3’FY25 (Rs. 321 Mn) vs loss of Rs. 276 Mn in Q3’FY24 on account of growth in operational revenue and optimization of 247 operating cost.

Omnichannel Healthcare Division:

Omnichannel Pharmacy (AHL+ APL) Business revenue of Rs 29,904 Mn in Q3’ FY25 compared to a revenue of Rs. 25,835 Mn in Q3’ FY24 (growth of 15.8%).

Apollo Telehealth (under AHEL) Revenues of Rs.167 Mn in Q3FY25 (growth of 9%)

: Digital Operational Metrics

Platform GMV : Rs 7,599 Mn in Q3’ FY25, growth of 11% over Q3’ FY24

New customer channel started to gain traction (launch of 19 mins across 4 cities)

Continuous Improvement in quantitative parameters in Q3’ FY25 vs Q3’ FY24:

25% YoY growth in Online Pharma delivered orders.
DAU Dec exit shows YoY growth of 25%

Offline Segment

12.2% YoY growth in offline transactions (8.04 cr Vs 7.17 cr year back).
O Serving ~8.7 lac offline customers per day

==> picture [49 x 56] intentionally omitted <==

==> picture [1152 x 6] intentionally omitted <==

(` mio)

==> picture [81 x 61] intentionally omitted <==

A ollo HealthCo Financials YTD Dec2 p 4

` Mio		Offline Pharmacy Distribution Online Pharmacy Distribution & Apollo 247 Total HealthCo
	Total Revenues	59,299 7,868 67,167
	**EBITDA (Pre 24	7 Cost)**
	margin (%)	7.6% 13.5% 8.3%
	24/7 Operating Cost	-3,634 -3,634
YTD D24	ESOP(Non Cash expense)	-621 -621
ec	EBITDA	4,508 -3,196 1,312
	margin (%)	7.6% - 2.0%
	EBIT PBT	897 382

	PAT(Reported)	382

	Total Revenues	51,388 6,614 58,002
	**EBITDA (Pre 24	7 Cost)**
	margin (%)	7.6% 11.2% 8.0%
	24/7 Operating Cost	-4,784 -4,784
YTD D23	ESOP(Non Cash expense)	-785 -785
ec	EBITDA	3,894 -4,828 -934
	margin (%)	7.6% - -

	EBIT	-1,303
	PBT	-1,777
	PAT(Reported)	-1,779

Revenue		15% 19% 16%
EBITDA(Pre 24	7 Cost)

==> picture [13 x 13] intentionally omitted <==

Healthco (YTD Dec 24 vs YTD Dec23);

16% growth in revenue in YTD ’FY25 vs YTD ’FY24
PAT positive in YTD ’FY25 (Rs. 382 Mn) vs loss of Rs.1,779 Mn in YTD ’FY24 on account of optimization of cost and growth in operational revenue.

Omnichannel Healthcare Division

Omnichannel Pharmacy Business (AHL + APL) revenue of Rs 84,820 Mn in YTD’ FY25 compared to a revenue of Rs. 73,069 Mn in YTD’FY24 (growth of 16.1%).

Apollo Telehealth (under AHEL) Revenue of Rs. 526 Mn in YTD FY25 (growth of 47%) compared to YTD FY24

: Digital Operational Metrics

Platform GMV : Rs 22,117 Mn in YTD FY25, growth of 7% over YTD ’ FY24

Offline Segment

o 12.5% YoY growth in offline transactions (22.8 cr Vs 20.3 cr year back).

==> picture [49 x 56] intentionally omitted <==

Excluding 24|7 operating Cost and ESOP Non-Cash Charge

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

A ollo HealthCo : Advent Investment - Tranche 1 of INR 1 2 crs com leted p 73 p

==> picture [49 x 56] intentionally omitted <==

Apollo Healthco Limited (“AHL”) to raise equity capital of INR 2,475 Crs (USD 300 Mn) from Advent International (“Advent”)[1] , one of the largest global private

equity investors with an AUM of over USD 94 Bn. Tranche 1 of INR 1,732 crs completed[2] and Tranche 2 of INR 743 crs will be completed in T+12 months.

I ntegration of Keimed Private Limited (“Keimed”) with AHL proposed in a phased manner.
Merger with Keimed estimated to be EPS accretive from Year 1.
To create India’s leading integrated pharmacy distribution business complemented by fast growing omni-channel digital health business.
Keimed is the market leader in wholesale pharma distribution with 2x the scale of nearest competitor and industry leading operating metrics. AHL to utilize

Keimed’s vast network of 70,000+ stores to accelerate its INR 1,500+ Crs (USD 0.18 Bn) private label portfolio.

Merged entity will have an industry defining business model with Pan India presence.
Target consolidated Year 3 revenues of ~INR 25,000 Crs[3 ] (USD 3.03 Bn) with operating margins* of 7-8%.
1 Rasmeli Limited, an affiliate of Advent International

2 The investment received from Advent International, in Apollo Healthco Ltd in the form of Compulsorily Convertible Preference shares (CCPs) is recorded as a Financial liability under IND AS 32 as the CCPs though will be fully Equity settled, could have some variability pursuant to the adjustments in accordance with the transaction agreements. Management does not expect any material variability from the 12.125% effective share holding of Advent in the Combined entity (Apollo Helathco Ltd including Keimed Private Limited).

3 On a Proforma Basis
*Post 24/7 Operating Cost

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

S ner etic Benefit of the Keimed Mer er y g g

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

Becoming India’s Leading Healthcare Provider

End-to-end, Patient retention Leading Pharma Distributor seamless, omnichannel User satisfaction + business model of pharmacy Cross selling Growing Omni distribution with a Apollo Channel Platform fast-growing digital HealthCo Ltd Inorganic Operator platform acquisitions With increased balance sheet capability

==> picture [41 x 55] intentionally omitted <==

... with Improving Cost Efficiency and Margins

Supply chain efficiencies , together with above permanently changes AHL’s margins, allowing for a growth story that outpaces our status quo.

EBITDA expansion in both AHL and Keimed over the next 2 years

==> picture [36 x 37] intentionally omitted <==

Integrated Business Model Driving Revenue Growth…

+70,000 serviced pharmacies Leveraging 2x scale vs. nearest competitor Keimed’s Infrastructure 96 24/7 operated distribution centres c.6,000 experienced employees

Faster penetration into Tier 2/3 markets, with scale flexibility + Drives private label crossselling , a higher margin business vs. pharma

This alone creates incremental EBITDA pool which is c.65% of Keimed EBITDA & Margin

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Proposed Transaction Structure and Steps (1/2)

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

==> picture [713 x 378] intentionally omitted <==

----- Start of picture text -----

Post Advent Tranche 1 Investment
Pre-Transaction
(T)
AHEL ESOP AHEL Advent ESOP
95% 5% 83.1% 12.5% [1] 4.4%
2%
AHL
AHL Keimed
----- End of picture text -----*

==> picture [401 x 378] intentionally omitted <==

----- Start of picture text -----

Post Advent Tranche 2 Investment
(T+12 Months)
AHEL Advent ESOP
79.0% 16.9% 4.1%
11.2%
AHL Keimed
----- End of picture text -----

Tranche 1

Advent investment of INR 1,732 Cr (USD 0.21 Bn) in AHL
AHL to acquire stake in Keimed for INR 125 Cr (USD 0.02 Bn)

Tranche 2

Advent investment of INR 743 Cr (USD 0.09 Bn) in AHL
• AHL to acquire stake in Keimed for INR 600 Cr (USD 0.07 Bn)

* ESOP Pool of 5% represents the increased pool which is yet to be implemented ;[1] On an as-if converted basis, the stake would be 16.9%. However, since certain shares are partly paid-up, % has been shown to that extent.

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Proposed Transaction Structure and Steps (2/2)

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

==> picture [1093 x 465] intentionally omitted <==

----- Start of picture text -----

Launch of Merger Process Post Merger
(T+15 Months) (T+30 Months)
Keimed
AHEL
Promoters
Keimed
AHEL
79.0% 61.5% Shareholders
Other minority
Advent ESOP FHPL 59.2% 25.7% [#]
partners
Min Max
16.9% 4.1% 16.1% 11.2%
Advent ESOP
12.1% [+] 3.0%
11.2%
AHL Keimed
Consolidation with AHL
1
2
Consolidation with Keimed
AHL
Various JVs
Post Primary Infusion of INR 100 crs and Secondary purchase of INR 625 crs by AHL
----- End of picture text -----**

Internal restructuring of Keimed Group; Post restructuring all JV’s to be 100% 1 owned by Keimed

Keimed is proposed to be merged with AHL through a scheme of arrangement with NCLT approval

** Includes economic interest of AHEL holding of 49% in FHPL; AHEL effective economic interest through FHPL post merger process is 2.5% ; # Includes 3.6% of Keimed minority partners ; + may be adjusted upwards pursuant to the adjustments in accordance with transaction agreements

==> picture [1152 x 6] intentionally omitted <==

(` mio)

==> picture [81 x 61] intentionally omitted <==

Combined Financials Metrix Sna shot YTD Dec2 | p 4

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

==> picture [1110 x 428] intentionally omitted <==

----- Start of picture text -----

Offline Pharma Online Pharma Combined Combined
FY24 Total Healthco Keimed Combined
Distribution Distribution+247
YTD’FY25 Q3’FY25
Revenue 59,299 7,868 67,167 96,534 121,318 42,355
137,701
EBITDA,Pre 9,614 4,348 1,029 5,377 3,002 8,379 2,953
INDAS
EBITDA % 7.0% 7.3% 13.1% 8.0% 3.1% 6.9% 7.0%
24/7
- -
Operating -6,186 -3,634 -3,634 -3,634 -1,137
cost
ESOP Non - -
-891 -268
-621 -621 -621
Cash charge
EBITDA,Pre IndAS 2,533 4,348 -3,225 1,123 3,002 4,125 1,547
EBITDA % 1.8% 7.3% N.M. 1.7% 3.1% 3.4% 3.7%
----- End of picture text -----

Excluding Digital

==> picture [104 x 32] intentionally omitted <==

----- Start of picture text -----

6.7%
----- End of picture text -----

6.5%

==> picture [104 x 32] intentionally omitted <==

----- Start of picture text -----

6.5%
----- End of picture text -----

At 22% annual CAGR on FY24, we expect to achieve INR 250 bn of revenue in FY27 with 7-8% EBITDA

==> picture [1152 x 6] intentionally omitted <==

Annexure

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

Basis of Consolidation

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

Subsidiaries	Location	Description	AHEL Ownership
Material Subs
Apollo Health Co limited	India	Digital Omni-Channel Healthcare services Platform	100.00%
Apollo Health and Lifestyle Ltd.	India	Clinics,Diagnostics and Daycare	68.84%
Apollo MultispecialityHospitals Ltd.	Kolkata	Hospital	100.00%
Apollo Medics	Lucknow	Hospital	51.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Assam Hospitals Ltd	Assam	Hospital	70.87%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
Other Subs
Apollo Hospitals(UK)Ltd	UK	UK Hold Co	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health	India	CSR	100.00%
Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co	100.00%
Future ParkingPvt Ltd	Chennai	Infrastructure	100.00%
Apollo Home Health care Ltd	India	Paramedical Services	74.00%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapien Bioscienses Pvt Ltd	Hyderabad	Biobankingtissues	70.00%
Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital	51.00%
Apollo Hospitals North Limited	Gurgaon	Hospital	100.00%
Apollo Hospitals Worli LLP	Mumbai	Hospital	90.10%
Health Axis	Hyderabad	Healthcare Technologies and Remote healthcare	69.99%
Kerala First Health Services Private Limited	Kerala	Hospital	60.00%
Associates	Location	Description
Indraprastha Medical Corporation Ltd.	Delhi,Noida	Hospital	22.03%
FamilyHealth Plan Ltd.	India	TPA,Health Insurance	49.00%
ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre	50.00%
Stemcyte India Therapautics Pvt Ltd	India	Stemcell Banking	37.75%
Apollo Gleneagles PET-CT Pvt Ltd	Hyderabad	Diagnostics	50.00%

==> picture [1152 x 6] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

IND AS - 116 : Im act on P&L and Balance Sheet –YTD Dec2 p 4

==> picture [13 x 13] intentionally omitted <==

==> picture [49 x 56] intentionally omitted <==

AHEL Standalone (post IND AS 116)

AHEL Consolidated (post IND AS 116)

Balance sheet Profit & Loss

Profit & Loss

Balance sheet Right of use Asset as of 31st Dec, 2024 12,803 Lease liabilities as of 31st Dec, 2024 12,796 Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) 2,109	Balance sheet Right of use Asset as of 31st Dec, 2024 12,803 Lease liabilities as of 31st Dec, 2024 12,796 Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) 2,109	Profit & Loss Revenue Other expenses (Lease rent) 769 EBITDA 769 Amortisation 472 EBIT 297 Finance charge 518 PBT 221	Profit & Loss Revenue Other expenses (Lease rent) 769 EBITDA 769 Amortisation 472 EBIT 297 Finance charge 518 PBT 221	Balance sheet Right of use Asset as of 31st Dec, 2024 23,896 Lease liabilities as of 31st Dec, 2024 25,361 Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) 3,052	Balance sheet Right of use Asset as of 31st Dec, 2024 23,896 Lease liabilities as of 31st Dec, 2024 25,361 Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) 3,052	Profit & Loss	Profit & Loss
Right of use Asset as of 31st Dec, 2024	12,803	Revenue		Right of use Asset as of 31st Dec, 2024	23,896	Revenue
		Other expenses (Lease rent)	769			Other expenses (Lease rent)	1,786
Lease liabilities as of 31st Dec, 2024	12,796			Lease liabilities as of 31st Dec, 2024	25,361
		EBITDA	769			EBITDA	1,786
		Amortisation	472			Amortisation	1,171
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	2,109			Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	3,052
		EBIT	297			EBIT	615
		Finance charge	518			Finance charge	1,139
		PBT	221			PBT	524

==> picture [1152 x 6] intentionally omitted <==

AI assistant

Apollo Hospitals Enterprises Ltd. — Interim / Quarterly Report 2025

63527_rns_2025-02-10_989f5eae-d9fb-47d4-ac2a-840e6f656a04.pdf

Apollo Hospitals Enterprise Limited Earnings Update Q3 FY25

Disclaimer

Content

^PD:- Pharmacy Distribution

^PD:- Pharmacy Distribution

AHLL: Transformin Retail Health throu h access and convenience g g

Apollo Health & Lifestyle Ltd

AHL| India’s Largest Omni-channel Healthcare Platform

Apollo 24|7

Apollo Telehealth*

Offline Pharmacy Distribution

Unmatched Size

Full stack digital healthcare platform

Clinical Updates and New Initiatives

Hospitals

AHLL

Apollo HealthCo

Consolidated Financials

Consolidated Financials Q3FY25

Consolidated Financials YTD Dec24

Healthcare Services Hospitals

Healthcare Services Financials

In atients Revenue Mix YTD Dec2 p 4

Healthcare Services : O erational Sna shot p p

Non Metros (includes Tier1 & Tier2 cities)

Tamil Nadu Region

Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore

Expansion Plan

AP Telan ana Re ion , g g

Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada

Karnataka Re ion g

Metro:- Bangalore; Non Metro:- Mysore

Expansion Plan

Eastern Re ion g

Metro:- Kolkata; Non Metro:- Guwahati, Bhubaneshwar, Bilaspur and Rourkela

Expansion Plan

Western Re ion g

Metro:- Navi Mumbai; Non Metro:- Nashik and Ahmedabad

Expansion Plan

Northern Re ion g

Metro:- Delhi; Non Metro:- Lucknow and Indore

Healthcare Services: Ex ansion Plan p

Diagnostics & Retail Health Apollo Health & Lifestyle Ltd

Executive Summar y

Specialty Care

AHLL Financials FY2 Q3 5

AHLL Financials YTD Dec2 4

Gross Revenue (INR Mn)

1. EBITDA post IND AS 116;

EBITDA (INR Mn)[1]

Network Growth – Collection Centers[#]

Digital Health & Pharmacy Distribution Apollo HealthCo

’ - India s Largest Omni Channel Healthcare Platform

A ollo HealthCo Financials FY2 p Q3 5

Digital Cash loss* (in Mn)

Healthco Cash profit* (in Mn)

Healthco (Q3’ FY25 vs Q3’ FY24);

Omnichannel Healthcare Division:

: Digital Operational Metrics

Offline Segment

A ollo HealthCo Financials YTD Dec2 p 4

Healthco (YTD Dec 24 vs YTD Dec23);

Omnichannel Healthcare Division

: Digital Operational Metrics

Offline Segment

A ollo HealthCo : Advent Investment - Tranche 1 of INR 1 2 crs com leted p 73 p

S ner etic Benefit of the Keimed Mer er y g g

Becoming India’s Leading Healthcare Provider

... with Improving Cost Efficiency and Margins

Integrated Business Model Driving Revenue Growth…

Proposed Transaction Structure and Steps (1/2)

Tranche 1

Tranche 2

Proposed Transaction Structure and Steps (2/2)

Combined Financials Metrix Sna shot YTD Dec2 | p 4

Annexure

Basis of Consolidation

Apollo Hospitals Enterprises Ltd. Interim / Quarterly Report 2025

**Digital Cash loss* (in Mn)**

**Healthco Cash profit* (in Mn)**